This review reframes diabetes as an active metabolic determinant of PC rather than a coincidental comorbidity and highlights metabolism-centered precision strategies as promising avenues for improving risk stratification, therapeutic decision-making, and clinical outcomes in diabetes-associated PC.
Diabetes mellitus and cancer are among the most prevalent chronic diseases worldwide, and accumulating evidence suggests a significant association between these conditions. The metabolic disturbances characteristic of diabetes, including hyperglycemia, hyperinsulinemia, insulin resistance, and chronic inflammation, cre...
Nahed S. Alharthi· American Journal of Cancer R...· 0 citations
Summary Diabetes mellitus substantially increases the risk of cardiovascular, cerebrovascular, renal, retinal and peripheral vascular complications. These are collectively referred to as diabetic panvascular disease. A traditional approach that treats each complication separately is no longer sufficient. An emerging fr...
Breast cancer remains the most frequently diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide. Despite substantial advances in endocrine therapy, human epidermal growth factor receptor 2 (HER2)-targeted therapy, chemotherapy, and immunotherapy, therapeutic resistance and metastati...
Jie Yuan, Hua Zhang, Jun Huang et al.· Biochimica et biophysica act...· 0 citations
Gestational diabetes mellitus (GDM) and cancer develop in distinct clinical and biological contexts; however, both conditions expose tissues to chronic metabolic stress, hypoxia, inflammation, and vascular remodelling. In this review, we advance the hypothesis that GDM and cancer share conserved endothelial adaptive re...
Katherin Silva, Paola Valero, G. Fuentes et al.· Molecular Aspects of Medicin...· 0 citations
Cancer has traditionally been viewed as a genetic disease driven by accumulated mutations; however, growing evidence indicates that metabolic dysregulation also plays an important role in tumor initiation and progression. This review aims to evaluate the evidence supporting a systemic metabolic perspective of cancer by...
The global cancer burden is projected to escalate to 27 million new cases annually by 2040, a trajectory that parallels the rising prevalence of obesity, metabolic dysfunction, and related metabolic disorders. While genetic and environmental factors are well-recognized, the systemic metabolic environment is increasingl...
